Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tasimelteon - Vanda Pharmaceuticals

Drug Profile

Tasimelteon - Vanda Pharmaceuticals

Alternative Names: BMS-214778; HETLIOZ; VEC-162

Latest Information Update: 14 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Vanda Pharmaceuticals
  • Class Amides; Antidepressants; Benzofurans; Cyclopropanes; Sleep disorder therapies; Small molecules
  • Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Circadian rhythm sleep disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Circadian rhythm sleep disorders
  • Discontinued Major depressive disorder

Most Recent Events

  • 14 Dec 2018 Vanda Pharmaceuticals announces intention to meet with regulatory authorities and seek marketing authorization for Circadian rhythm sleep disorders (Smith-Magenis Syndrome)
  • 10 Dec 2018 Efficacy data from a phase II/III trial in Circadian rhythm sleep disorders (Smith-Magenis Syndrome) released by Vanda Pharmaceuticals
  • 30 Sep 2018 Vanda Pharmaceuticals completes enrolment in a phase II/III trial in Circadian rhythm sleep disorders (Smith-Magenis Syndrome) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top